Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada - Concepedia

Concepedia

Publication | Closed Access

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

45

Citations

42

References

2014

Year

C Attard, Amber N. Pepper, S. T. Brown, Melissa F Thompson, Per-Olof Thuresson, S. Yunger, Susan Dent, Alexander Paterson, George A. Wells

Journal of Medical Economics

Abstract

Given the improvement in clinical efficacy and a favorable cost per QALY, the addition of pertuzumab in the neoadjuvant setting represents an attractive treatment option for HER2-positive eBC patients.

References

	Year	Citations

Page 1